Osteoporosis

CVRM · 3 drugs · 3 indications

Competitive Landscape (3 drugs)
DrugCompanyMechanismModalityRouteStage
EvenityAMGN, UCBSclerostin inhibitorAntibodySCAPPROVED
ProliaAMGNRANK ligand inhibitorMonoclonal antibodySCAPPROVED
XGEVAAMGNRANK ligand inhibitorMonoclonal antibodySCAPPROVED
Indications (3)
Postmenopausal osteoporosis
Evenity APPROVED
Postmenopausal Osteoporosis
Prolia APPROVED
Bone metastases (solid tumors)
XGEVA APPROVED
Upcoming Catalysts
Evenity - Commercial Uptake (with Amgen)COMMERCIAL
UCB2026
Data from Supabase · Updated 2026-03-24